BOMT (original) (raw)
BOMT, also known by its developmental code name Ro 7-2340 and as 6α-bromo-4-oxa-17α-methyl-5α-dihydrotestosterone, is a synthetic steroidal antiandrogen which was first developed in 1970 and was never marketed for medical use. It is the 6α-brominated, 4-oxygenated, and 17α-methylated derivative of the androgen dihydrotestosterone (DHT). Along with benorterone, cyproterone (and its C17α acetate ester, cyproterone acetate), and flutamide, BOMT was among the earliest antiandrogens to be developed and extensively studied, although it is less well-documented in comparison to the others. BOMT has been investigated clinically in the treatment of benign prostatic hyperplasia, though development for this use did not continue. There was also interest in BOMT for the potential applications of acne, p
| Property | Value |
|---|---|
| dbo:abstract | BOMT, also known by its developmental code name Ro 7-2340 and as 6α-bromo-4-oxa-17α-methyl-5α-dihydrotestosterone, is a synthetic steroidal antiandrogen which was first developed in 1970 and was never marketed for medical use. It is the 6α-brominated, 4-oxygenated, and 17α-methylated derivative of the androgen dihydrotestosterone (DHT). Along with benorterone, cyproterone (and its C17α acetate ester, cyproterone acetate), and flutamide, BOMT was among the earliest antiandrogens to be developed and extensively studied, although it is less well-documented in comparison to the others. BOMT has been investigated clinically in the treatment of benign prostatic hyperplasia, though development for this use did not continue. There was also interest in BOMT for the potential applications of acne, pattern hair loss, and possibly prostate cancer, but it was not developed for these indications either. BOMT is a selective competitive antagonist of the androgen receptor (AR), although it is described as an "only relatively weak competitor." The relative binding affinity of the drug for the androgen receptor is about 2.7% of that of metribolone. BOMT shows no androgenic, estrogenic, or progestogenic activity even at high doses, nor any inhibition of 5α-reductase, though it has been reported to possess weak antigonadotropic effects. Due to its selectivity for and competitive inhibition of the AR, BOMT has been described as a pure or "true" antiandrogen, similarly to benorterone, cyproterone, and flutamide. Like other steroidal antiandrogens, BOMT may actually be a weak partial agonist of the AR, as it appears to have the potential for weak androgenic effects in specific situations. On the basis of animal research, BOMT does not appear to act as an AR antagonist in central nervous system tissues, and in relation to this, does not disinhibit the hypothalamic–pituitary–gonadal axis or increase testosterone levels. (en) |
| dbo:casNumber | 24543-59-7 24543-66-6 |
| dbo:class | dbr:Steroidal_antiandrogen |
| dbo:pubchem | 159972 |
| dbo:thumbnail | wiki-commons:Special:FilePath/BOMT.svg?width=300 |
| dbo:wikiPageID | 51298731 (xsd:integer) |
| dbo:wikiPageLength | 12518 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1084694042 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:5α-reductase dbr:Benign_prostatic_hyperplasia dbr:Enzyme_inhibitor dbr:Partial_agonist dbr:Progestogen dbr:Animal_research dbr:Benorterone dbr:Androgen dbr:Androgen_receptor dbc:Abandoned_drugs dbc:Androstanes dbc:Bromoarenes dbc:Lactones dbc:Steroidal_antiandrogens dbc:Tertiary_alcohols dbr:Competitive_antagonist dbr:Chemical_synthesis dbr:Ester dbr:Estrogen_(medication) dbr:Oral_administration dbr:Prostate_cancer dbr:Bromine dbr:Acetate dbr:Cyproterone dbr:Cyproterone_acetate dbr:Flutamide dbr:Oxygen dbr:Central_nervous_system dbc:Drugs_for_benign_prostatic_hyperplasia dbr:Testosterone dbr:Hypothalamic–pituitary–gonadal_axis dbr:Acne dbr:Binding_selectivity dbr:Tissue_(biology) dbr:Dihydrotestosterone dbr:Metribolone dbr:Methyl_group dbr:List_of_steroidal_antiandrogens dbr:Pattern_hair_loss dbr:Steroidal_antiandrogen dbr:Chemical_derivative dbr:Relative_binding_affinity dbr:Antigonadotropic |
| dbp:atcPrefix | None (en) |
| dbp:br | 1 (xsd:integer) |
| dbp:c | 19 (xsd:integer) |
| dbp:casNumber | 24543 (xsd:integer) |
| dbp:casSupplemental | 24543 (xsd:integer) |
| dbp:chemspiderid | 140636 (xsd:integer) |
| dbp:class | dbr:Steroidal_antiandrogen |
| dbp:h | 29 (xsd:integer) |
| dbp:iupacName | -5 (xsd:integer) |
| dbp:o | 3 (xsd:integer) |
| dbp:pubchem | 159972 (xsd:integer) |
| dbp:routesOfAdministration | dbr:Oral_administration |
| dbp:smiles | CC12CCCOC1CBr (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | ZUIGZKIOHUNINA-LWPUPYOYSA-N (en) |
| dbp:synonyms | Ro 7-2340; 6α-Bromo-4-oxa-17α-methyl-5α-dihydrotestosterone; 6α-Bromo-4-oxa-17α-methyl-5α-androstan-17β-ol-3-one (en) |
| dbp:width | 225 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Androgen_receptor_modulators dbt:Drugbox dbt:Reflist dbt:Short_description |
| dcterms:subject | dbc:Abandoned_drugs dbc:Androstanes dbc:Bromoarenes dbc:Lactones dbc:Steroidal_antiandrogens dbc:Tertiary_alcohols dbc:Drugs_for_benign_prostatic_hyperplasia |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | BOMT, also known by its developmental code name Ro 7-2340 and as 6α-bromo-4-oxa-17α-methyl-5α-dihydrotestosterone, is a synthetic steroidal antiandrogen which was first developed in 1970 and was never marketed for medical use. It is the 6α-brominated, 4-oxygenated, and 17α-methylated derivative of the androgen dihydrotestosterone (DHT). Along with benorterone, cyproterone (and its C17α acetate ester, cyproterone acetate), and flutamide, BOMT was among the earliest antiandrogens to be developed and extensively studied, although it is less well-documented in comparison to the others. BOMT has been investigated clinically in the treatment of benign prostatic hyperplasia, though development for this use did not continue. There was also interest in BOMT for the potential applications of acne, p (en) |
| rdfs:label | BOMT (en) |
| owl:sameAs | yago-res:BOMT wikidata:BOMT https://global.dbpedia.org/id/2czKm |
| prov:wasDerivedFrom | wikipedia-en:BOMT?oldid=1084694042&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/BOMT.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:BOMT |
| is dbo:wikiPageRedirects of | dbr:C19H29BrO3 dbr:Ro–7–2340 dbr:RO-7-2340 dbr:RO-72340 dbr:RO7-2340 dbr:RO72340 dbr:RO_7-2340 dbr:RO_72340 dbr:RO–7–2340 dbr:Ro-7-2340 dbr:Ro-72340 dbr:Ro7-2340 dbr:Ro72340 dbr:Ro_7-2340 dbr:Ro_72340 |
| is dbo:wikiPageWikiLink of | dbr:Benorterone dbr:Antiandrogen dbr:Trimethyltrienolone dbr:C19H29BrO3 dbr:Cyproterone dbr:Cyproterone_acetate dbr:DIMP_(antiandrogen) dbr:List_of_steroidal_antiandrogens dbr:Steroidal_antiandrogen dbr:Ro–7–2340 dbr:RO-7-2340 dbr:RO-72340 dbr:RO7-2340 dbr:RO72340 dbr:RO_7-2340 dbr:RO_72340 dbr:RO–7–2340 dbr:Ro-7-2340 dbr:Ro-72340 dbr:Ro7-2340 dbr:Ro72340 dbr:Ro_7-2340 dbr:Ro_72340 |
| is foaf:primaryTopic of | wikipedia-en:BOMT |
